Abstract Ayurvedic medicine plants continue to draw attention for the discovery of novel anticancer agents. Withaferin A (WA) is one such small-molecule constituent of the ayurvedic medicine plant Withania somnifera with efficacy against cultured and xenografted human breast cancer cells. However, the mechanism underlying anticancer effect of WA is not fully understood.
Introduction
Breast cancer continues to be a leading cause of cancerrelated deaths among women worldwide despite screening efforts for early detection of the disease, as well as major chemotherapeutic advances involving targeted therapies [1] [2] [3] . Novel strategies for prevention and treatment of breast cancer are desirable to diminish disease-related cost, mortality, and morbidity associated with this disease. Constituents of ayurvedic medicine, which has been practiced in India for thousands of years for the treatment of different ailments, continue to gain interest for the discovery of novel anticancer agents [4] . Withania somnifera (commonly known as Ashwagandha or Indian winter cherry) is one such medicinal plant with a broad spectrum pharmacological effects in experimental models, including cardioprotection from ischemia reperfusion injury [5] , inhibition of 6-hydroxydopamine-induced Parkinsonism [6] , antibacterial properties [7] , immunomodulatory effects [8] , and anticancer effects [9] [10] [11] [12] . For instance, oral feeding of leaf extract of Ashwagandha resulted in growth retardation of HT1080 human fibrosarcoma in athymic mice [10] . Likewise, benzo[a]pyrene-induced forestomach tumor incidence and multiplicity were significantly inhibited by dietary administration of W. somnifera root [11] .
Anticancer effect of W. somnifera is believed to be due to withanolides including withaferin A (WA) [13] [14] [15] [16] [17] . WA treatment was shown to cause destruction of ehrlich ascites tumor cells in vivo by causing immune activation [13] . Oral administration of WA for 14 weeks resulted in complete protection against 7,12-dimethylbenz [a] anthracene-induced oral carcinogenesis in hamsters [17] . The WA-mediated inhibition of human cancer cells implanted in athymic mice has also been reported [15, 16] . For example, studies from our own laboratory have shown WA-mediated inhibition of MDA-MB-231 human breast cancer xenograft growth in female athymic mice [16] . Moreover, the WA treatment inhibited breast cancer invasion and metastasis in vivo [18] .
The mechanism underlying anticancer effect of WA is not fully understood, but the known effects following treatment with this agent in cultured cancer cells comprise G 2 /M phase and mitotic arrest [19] , reactive oxygen species-dependent apoptosis [20, 21] , and suppression of multiple oncogenic pathways including signal transducer and activator of transcription 3 [22] , estrogen receptor-a [23] , and nuclear factorjB [24] . Because pathogenesis of cancer is complex often involving activation of multiple oncogenes and deregulation of various checkpoints, targeting of multiple pathways with a single small-molecule is desirable for clinical management of cancer. Agent active against a single molecular target or pathway may have limited clinical utility as exemplified by estrogen receptor antagonists [25] .
The Notch pathway regulates expression of genes involved in cell fate determination including proliferation and differentiation [26, 27] . The Notch pathway is implicated in mammary carcinogenesis [28] [29] [30] [31] . The WA was previously shown to inhibit Notch1 activation in human colon cancer cells [32] . The Notch signaling is quite complex involving interplay between four receptors (Notch1-Notch4) and five ligands (Jagged1, Jagged2, Delta-like ligand 1, ligand 3, and ligand 4). The primary objective of this study was to determine the role of Notch2 and Notch4 in anticancer effects of WA using human breast cancer cells as a model.
Materials and methods

Reagents
The WA was purchased from Enzo Life Sciences (Farmingdale, NY) and its structural analogs (withanone and withanolide A) were purchased from ChromaDex (Irvine, CA). Dimethyl sulfoxide (DMSO), 4 0 ,6-diamidino-2-phenylindole (DAPI), and anti-actin antibody were purchased from Sigma-Aldrich (St. Louis, MO). Reagents for cell culture including media, antibiotic mixture, and fetal bovine serum, and Alexa Flour-488 conjugated anti-rabbit antibody were purchased from Invitrogen-Life Technologies (Carlsbad, CA). The antibody against cleaved Notch1, Notch2, Jagged1, Jagged2, presenilin1, and nicastrin were from Cell Signaling Technology (Danvers, MA). An antibody specific for detection of cleaved Notch2 was from EMD Millipore (Billerica, MA). Anti-cleaved Notch1 antibody used for immunofluorescence microscopy was purchased from Abcam (Cambridge, MA). The antibodies against Notch1 and Notch4 (this antibody recognizes both transmembrane and cleaved forms of the protein), were from Santa Cruz Biotechnology (Santa Cruz, CA). Control non-specific small interfering RNA (siRNA) was purchased from Qiagen (Valencia, CA). The Notch2-targeted siRNA, Notch4-targeted siRNA, control small-hairpin RNA (shRNA), and Notch2-targeted shRNA were from Santa Cruz Biotechnology. Transwell TM chamber was purchased from Corning (Corning, NY).
Cell lines
The MDA-MB-231, MDA-MB-468, and MCF-7 cells were obtained from the American Type Culture Collection (Manassas, VA) and maintained as described by us previously [16] or recommended by the supplier. The MDA-MB-231 cells were stably transfected with Notch2 shRNA and control shRNA as described elsewhere [33] . Stock solutions of WA and its analogs were prepared in DMSO (final concentration \0.1 %), and an equal volume of DMSO was added to the controls.
Western blotting
After desired treatment, the cells were collected and processed for immunoblotting as described by us previously [33, 34] . Immunoreactive bands were visualized using enhanced chemiluminescence reagent.
Immunocytochemistry
The MDA-MB-231 or MCF-7 cells (1 9 10 5 ) were plated on coverslips and allowed to attach by overnight incubation. The cells were treated with different concentrations of WA for 24 h, fixed with 2 % paraformaldehyde for 1 h at room temperature, permeabilized with 0.5 % Triton X-100 for 10 min, and blocked with phosphate-buffered saline (PBS) supplemented with 0.5 % bovine serum albumin and 0.15 % glycine for 1 h. The cells were incubated overnight with antibody against cleaved Notch1 or cleaved Notch2 at 4°C, and then treated with 2 lg/ml of Alexa Fluor 488-conjugated secondary antibody for 1 h at room temperature. The cells were washed with PBS, counterstained with DAPI for 5 min at room temperature, mounted and observed under a Leica DC300F fluorescence microscope at 1009 objective magnification.
Luciferase reporter assay RBP-Jk luciferase reporter kit (SABiosciences-Qiagen) was used to determine the effect of WA treatment on transcriptional activity of Notch. The HES-1A/B and HEY-1 luciferase reporter constructs were generously provided by Dr. Kimberly E. Foreman (Department of Pathology, Loyola University Medical Center, Maywood, IL) [35] . Luciferase activity was determined as described by us previously [33] .
Reverse transcription (RT)-PCR and real-time quantitative PCR
Total RNA from control and WA-treated cells was isolated using RNeasy kit from Qiagen. cDNA was synthesized and reversed transcribed using Oligo(dT) 20 primer and SuperScript III Reverse Transcriptase. The PCR was performed using GoTaq Green Master Mix (Promega, Madison, WI) and primers as described by us previously [36] . The RT-PCR primers and amplification conditions for Notch4 were: forward 5 0 -TAGGGCTCCCCAGCTCTC-3 0 , reverse 5 0 -GGCAGGTGCCCCCATT-3 0 (95°C for 5 min followed by 35 cycles of 95°C for 30 s, 60°C for 1 min, and 72°C for 30 s). Quantitative real-time PCR was performed using SYBR Green master mix (Applied Biosystems, Foster City, CA) on ABI StepOnePlus system (Applied Biosystems). Relative gene expression was normalized against GAPDH.
Cell growth assay
Cells were seeded into 96-well plates and allowed to attach. After 48 h of treatment with DMSO or WA, cell proliferation was determined using the CellTiter96 AQueous Non-Radioactive Cell Proliferation Assay (Promega) according to the manufacturer's protocol.
Cell migration assay
The MDA-MB-231 or MDA-MB-468 cells were transfected with desired siRNA. Cell migration assay was performed as described by us previously [33, 36] using a Boyden chamber containing an 8 lm filter. Motile cells on the bottom face of the filter were fixed with methanol and stained with hematoxylin and eosin. At least three nonoverlapping areas on each filter were scored for cell migration.
Wound healing assay
The MDA-MB-231 cells stably transfected with control shRNA or Notch2-targeted shRNA were seeded in 6-well plates. A monolayer of confluent cells was scratched with a pipette tip. The wounded cells were washed with PBS and incubated with RPMI-1640 medium containing 1 % fetal bovine serum, puromycin (1 lg/ml), 1 mM thymidine, and desired concentrations of WA. The cells were allowed to migrate for 16 h, fixed with methanol, and stained with Giemsa staining solution. At least three non-overlapping areas were examined for wound healing.
Results
Effect of WA treatment on cleavage of Notch1, Notch2, and Notch4 in human breast cancer cells
Final step of Notch activation involves cleavage of the receptor at a site located within the transmembrane domain mediated by the c-secretase complex. Consistent with published results in colon cancer cells [32] , the WA treatment resulted in a marked decrease in levels of transmembrane as well as cleaved (active) Notch1 in MDA-MB-231 and MCF-7 cells, which, respectively, are well-studied representatives of estrogen-independent and estrogen-responsive human breast cancer cells (Fig. 1a) . On the other hand, levels of cleaved Notch2 as well as cleaved Notch4 were increased markedly upon a similar treatment with WA in both cell lines (Fig. 1a) . Effect on cleaved Notch2 was relatively more pronounced in the MDA-MB-231 cell line compared with MCF-7, whereas an opposite trend was discernible on cleavage of Notch4. The WA-mediated cleavage of Notch2 and Notch4 was accompanied by a decrease in levels of respective transmembrane proteins (Fig. 1a) . Opposing effect of WA treatment on levels of cleaved Notch1 (Fig. 1b) and cleaved Notch2 (Fig. 1c) interest to determine overall impact on transcriptional activity of Notch. We approached this question by determining the effect of WA treatment on luciferase activities associated with RBP-Jk and downstream targets of Notch including HES-1A/B and HEY-1. Exposure of MDA-MB-231 and MCF-7 cells to WA resulted in a statistically significant increase in RBP-Jk-associated luciferase activity, which was accompanied by transcriptional activation of Notch downstream target HES-1A/B (Fig. 2) . However, the effect of WA treatment on HEY-1 luciferase activity was different between MDA-MB-231 and MCF-7 cells.
The WA-treated MDA-MB-231 cells exhibited a dose-and time-dependent increase in HEY-1 luciferase activity (Fig. 2) . On the other hand, the WA-mediated increase in HEY-1 luciferase reporter activity was transient in MCF-7 cells with the increase seen only at 8 h time point. Mechanisms underlying regulation of HEY-1 gene expression are not fully understood but its expression can also be regulated by Wnt10b as exemplified in osteosarcoma cells [37] . It is possible that the decrease in HEY-1 luciferase activity seen at the 24 h time point in WA-treated MCF-7 cells is a reflection of Wnt10b suppression. Collectively, these data Effects of WA treatment on Jagged1, Jagged2, presenilin1, and nicastrin protein levels
To further probe into the mechanism by which WA treatment increased cleavage of Notch2 and Notch4, we performed western blotting for Jagged1, Jagged2, and c-secretase complex components presenilin1 and nicastrin using lysates from control (DMSO-treated) and WA-treated MDA-MB-231 and MCF-7 cells (Fig. 3a) . Effect of WA treatment on protein levels of Jagged1 was different between MDA-MB-231 and MCF-7 cells. In MCF-7 cells, WA caused suppression of both Jagged1 and Jagged2 protein expression as early as 6 h after treatment, and this effect persisted for the duration of the experiment (Fig. 3a) . A marked decrease in levels of Jagged1 and Jagged2 proteins in MDA-MB-231 cells at both concentrations of WA was evident only at the 24 h time point (Fig. 3a) . At the same time, WA treatment resulted in a marked increase in presenilin1 (both cell lines) and nicastrin (MCF-7 cells) protein levels in MDA-MB-231 and MCF-7 cells and this effect generally persisted for the duration of the experiment (Fig. 3a) . To our surprise the levels of Notch1 mRNA were increased after treatment with WA in both cell lines (Fig. 3b) , whereas a decrease in Notch2 mRNA was discernible at 12 h time point (Fig. 3c) . The level of Notch4 mRNA was decreased after treatment with WA in MDA-MB-231 in a dose-and time-dependent manner as revealed by RT-PCR (Fig. 3d) . To the contrary, the WA-treated MCF-7 cells exhibited a biphasic response with an increase in Notch4 mRNA level at 6 h time point followed by its suppression after 12 h of treatment (Fig. 3d) . Because of variability in mRNA expression of different Notch we conclude that induction of presenilin1 and nicastrin likely accounts for WA-mediated cleavage of Notch2 and Notch4. However, additional work is necessary to substantiate this mechanistic possibility.
Notch2 knockdown augmented WA-mediated inhibition of cell viability and cell migration
We next proceeded to determine the role of Notch2 in WAmediated inhibition of cell proliferation and cell migration by (Fig. 4a ). Transient transfection with the Notch2-targeted siRNA alone resulted in a significant suppression of cell proliferation (Fig. 4b) as well cell migration (Fig. 4c) in both cell lines. Moreover, the WA-mediated inhibition of MDA-MB-231 and MDA-MB-468 cell proliferation (Fig. 4b) , as well as cell migration (Fig. 4d) was significantly augmented by RNA interference of Notch2. However, this augmentation effect was much more pronounced on cell migration (Fig. 4d ) than on cell proliferation (Fig. 4b) . We used MDA-MB-231 cells with stable transfection with a Notch2-targeted shRNA to further test its role in WA-mediated inhibition of cell migration. Level of (Fig. 5a ). Similar to the results using siRNA, the WA-mediated inhibition of MDA-MB-231 cell proliferation was modestly increased upon stable knockdown of Notch2 at least at the 1 lM concentration (Fig. 5b) . In addition, the MDA-MB-231 cells with stable transfection with Notch2-targeted shRNA were significantly more sensitive to WA-mediated inhibition of wound migration compared with control shRNA transfected cells (Fig. 5c,   d ). These results indicated that Notch2 activation by WA partially abrogated its inhibitory effect on cell migration.
Notch4 knockdown augmented WA-mediated inhibition of cell migration
We next studied the impact of Notch4 activation on WA's ability to inhibit cell proliferation and cell migration using MDA-MB-231 and MDA-MB-468 cells. Level of transmembrane Notch4 protein was decreased by 40 and [99 % upon transient transfection of MDA-MB-231 and MDA-MB-468 cells with a Notch4-targeted siRNA, respectively (Fig. 6a) . Unlike Notch2 siRNA (Fig. 4b) , RNA interference of Notch4 alone had minimal effect on cell proliferation in either cell line (Fig. 6b) . Furthermore, inhibition of cell proliferation resulting from WA exposure was not affected by RNA interference of Notch4 in either cell line (Fig. 6b) . On the other hand, WA-mediated inhibition of cell migration was significantly augmented by Notch4 knockdown (Fig. 6c,d ). This augmentation was relatively more pronounced in the MDA-MB-468 cell line than in the MDA-MB-231 cells possibly due to greater knockdown of the Notch4 protein in the former cell line. These results indicated that knockdown of Notch4 protein augmented WA-mediated inhibition of cell migration.
Effect of WA analogs on cell migration and Notch2 activation
We used a pair of WA analogs (structures shown in Fig. 7a ) to test whether inhibition of cell migration and/or activation of Notch2 were unique to WA. Initially, we compared WA, WE, and WLA for their efficacy against cell migration using MDA-MB-231 cells. The WE and WLA were practically ineffective against MDA-MB-231 cell migration (Fig. 7b) . In addition, neither WE nor WLA was able to cause an increase in levels of cleaved Notch2 at least in the MDA-MB-231 and MCF-7 cells except for a modest increase seen with WE in MCF-7 cells at the 1 and 2 lM concentrations (Fig. 7c) . These results indicated that even a subtle change in the withanolide structure could have a marked impact on its activity.
Discussion
Notch activation is linked to mammary carcinogenesis in both animal models and humans [28] [29] [30] [31] . For example, overexpression of activated Notch1 and Notch3 in transgenic mice was shown to block mammary gland development but induce tumorigenesis of the breast [28] . In humans, high level expression of Notch1 and its ligands is associated with poor outcome [29] [30] [31] . Furthermore, Jagged1 expression is associated with recurrence in lymph node-negative breast cancer [31] . Notch1 is involved in migration and invasion of human breast cancer cells [38] , whereas Notch4 receptor signaling is implicated in regulation of breast cancer stem cell activity [39] . In addition, induction of Notch1 activity and function by ErbB2 as well as cross-talk between Notch and estrogen receptor has also been demonstrated [40, 41] . Impetus to determine the effect of WA on Notch2 and Notch4 stemmed from the observations that this agent inhibits Notch1 activation in human colon cancer cells [32] . This study indicates that while WA treatment inhibits cleavage of Notch1 consistent with the results observed in colon cancer cells [32] , it is an activator of Notch2 as well as Notch4 in breast cancer cells. Whether or not WA activates Notch2 and/or Notch4 in colon or other cancer cells remains to be determined, but knockdown of these proteins clearly augments inhibitory effect of WA on cell migration. Importantly, the WA-mediated activation of Notch2 and Notch4 in breast cancer cells is evident at plasma achievable concentration of 2 lM [18] . The mechanism by which WA downregulates expression of Notch1 and inhibits its activation is unclear but this effect is not due to its transcriptional repression based on results shown on Fig. 3b . It is possible that WA treatment promotes proteasomal degradation of Notch1 and/or affects its translation. A role for prolyl-isomerase Pin1 in activation of Notch1 has also been proposed [42] . Pin1 has been shown to bind with Notch1 and promote its cleavage by the c-secretase [42] . Interestingly, Pin1 is a direct target of Notch1 creating a positive feedback loop. Consistent with the Pin1-Notch1 cooperation, levels of these proteins correlate in breast cancer [42] . Interestingly, our unpublished studies indicate that WA treatment downregulates Pin1 protein expression at least in the MCF-7 cell line (Singh SV, unpublished results). It is possible that Pin1 downregulation contributes to the suppression of transmembrane and/or cleaved Notch1 after treatment with WA. Additional work is needed to probe into these mechanisms.
We observed cell line-specific differences in effect of WA on extent of Notch activation. For example, the WA-mediated increase in level of cleaved Notch2 is relatively more pronounced in the MDA-MB-231 cells (up to 16.7-fold increase compared with DMSO-treated control), which has mutant p53, than in the wild-type p53 expressing MCF-7 cell line (up to 3.4-fold increase over DMSO-treated control). In contrast, WA-mediated cleavage of Notch4 was relatively more pronounced in the MCF-7 cells compared with MDA-MB-231 cells. Similar cell line-specific differences are also discernible with respect to effect of WA on c-secretase complex components. The molecular basis for these cell linespecific differences remains to be determined, but may be related to differences in p53 and/or Wnt/b-catenin status. The Wnt/b-catenin is constitutively active in the MCF-7 cells but not in the MDA-MB-231 cell line [43] .
This study reveals that Notch2 and Notch4 knockdown partially inhibits cell migration. Under these knockdown conditions, WA further inhibits cell migration. These results indicate that WA likely affects other pathways to inhibit breast cancer cell migration. Suppression of urokinase plasminogen activator (uPA) system consisting of the serine protease uPA and its glycolipid-anchored receptor (uPAR) is one such possibility to explain WA-mediated inhibition of cell migration. Previous studies have indicated that the uPA/uPAR system is causally involved not only in remodeling of the extracellular matrix but also enhancing cell proliferation and migration [44] . Our unpublished studies indicate that WA treatment suppresses uPA and uPAR protein levels in breast cancer cells (Lee J, Singh SV, unpublished results). The uPA is a direct transcriptional target of Jagged1-Notch signaling in breast cancer cells [45] . High uPA expression also correlates with breast cancer recurrence and metastasis [46] . Further studies are needed to experimentally address whether augmentation of WA-mediated inhibition of cell migration is related to suppression of the uPA/uPAR pathway.
